Antiphospholipid syndrome in patients over 65 years: A comparative study of clinical and biological features and thrombotic relapses

Abstract

Objective

The aim of the study was to describe clinical and biological characteristics and thrombotic relapses of patients diagnosed with antiphospholipid syndrome (APS) after the age of 65 years, in comparison with patients diagnosed with APS before 65.

Methods

This retrospective multicenter study was performed to 2005 from 2017 and included patients diagnosed with APS after the age of 65 years, in accordance with Sydney criteria. We compared these patients with APS patients diagnosed before the age of 65 years, and with control thrombotic patients older than 65 years.

Results

Fifty-eight APS patients over the age of 65 years were compared to 127 APS patients aged less than 65 and to 58 controls. In elderly APS versus younger APS, there was a male predominance (58.6% vs 36.2% p = .001); myocardial infarction and lower limb deep vein thrombosis (LLDVT) were more frequent in elderly, respectively, 12.1% versus 1.6% (p = .005), and 44.8% versus 29.9% (p = .048). Anticardiolipin antibody (aCL) IgM was more frequently found in old patients compared to younger patients (33.9% vs 18.1%, p = .02), contrary to lupus anticoagulant (LAC) (52.8% vs 66.9%, p = .02). Older patients were more often diagnosed with single positive APS (82.8% vs 59.8% p = .002). The thrombotic relapse free survival was lower in elderly APS patients (p = .044) compared to younger APS. Elderly APS patients had more recurrent arterial and venous thrombosis (p = .03) and had poorer overall survival (p = .004) than elderly controls.

Conclusion

In this study, APS was different in patients aged more than 65 years, with a male predominance and more myocardial infarctions and LLDVT at diagnosis. Single antiphopholipid positivity and aCL IgM were more frequent in older patients. Older patient with APS had more thrombotic recurrence during follow-up. Compared to elderly controls, elderly APS patients had more thrombosis recurrences and poorer survival.

Keywords

Antiphopholipid syndrome elderly IgM anticardiolipin antibody lupus anticoagulant

Get full access to this article

View all access options for this article.

References

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Wilson

Gharavi

Koike

, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309–1311.

Pengo

Tripodi

Reber

, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–1740.

Manoussakis

Tzioufas

Silis

, et al. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987; 69: 557–565.

Fields

Toubbeh

Searles

, et al. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989; 16: 623–625.

Engbers

Vlieg

AVH

Rosendaal

. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010; 8: 2105–2112.

Hutten

Lensing

Kraaijenhagen

, et al. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999; 14: 303–312.

Zuily

Clerc-Urmès

Bauman

, et al. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. Lupus 2020; 23: 961203320940776.

Grimaud

Yelnik

Pineton de Chambrun

, et al. Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study. Rheumatology (Oxford) 2019; 58: 1006–1010.

10.

Quéméneur

Lambert

Hachulla

, et al. Significance of persistent antiphospholipid antibodies in the elderly. J Rheumatol 2006; 33: 1559–1562.

11.

Cervera

Piette

Font

, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–1027.

12.

Zuckerman

Toubi

Golan

, et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 1995; 72: 447–451.

13.

Piette

Cacoub

. Antiphospholipid syndrome in the elderly: caution. Circulation 1998; 97: 2195–2196.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB